

Serial No. 10/633,762  
PC27272

### Claims

1. A method for treating or preventing hot flashes in a patient in need thereof comprising administering a therapeutically effective dose of a compound selected from reboxetine or S,S-reboxetine, a pharmaceutically acceptable salt thereof, a derivative thereof, or a prodrug thereof to the patient.
2. A method of claim 1, wherein the patient is female.
3. (Currently amended). A method according to claim 2, wherein the hot flashes are menopause or postmenopause ~~symptoms~~ symptoms.
4. A method according to claim 2, wherein the hot flashes are due to medical treatment.
5. A method according to claim 2, wherein the hot flashes are caused by radiation therapy.
6. A method according to claim 2, wherein the hot flashes are drug-induced.
7. A method according to claim 2, wherein the patient is receiving anti-estrogen therapy.
8. A method according to claim 2, wherein the patient is suffering from or has suffered from cancer.
9. A method according to claim 5, wherein the cancer is breast cancer.
10. A method according to claim 1, wherein the patient is male.
11. A method according to claim 10, wherein the hot flashes are caused by radiation therapy.
12. A method according to claim 10, wherein the hot flashes are drug-induced.

(Response to Election Requirement—page 2 of 5)

Serial No. 10/633,762  
PC27272

13. A method according to claim 10, wherein the patient has androgen deprivation.
14. A method according to claim 10, wherein the patient is suffering from or has suffered from cancer.
15. A method according to claim 14, wherein the cancer is prostate cancer or testicular cancer.
16. The method according to claim 1, wherein the reboxetine dose range is 4 to 10 mg per patient per day.
17. The method according to claim 1, wherein the reboxetine dose range is 6 to 8 mg per patient per day.
18. The method according to claim 1, wherein the compound is administered in the form of a pharmaceutical composition additionally comprising a pharmaceutically acceptable carrier or excipient.
- 19-22. (Canceled).

(Response to Election Requirement—page 3 of 5)